Rezolute Inc RZLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RZLT is a good fit for your portfolio.
News
-
Rezolute to Participate in the Jefferies Global Healthcare Conference
-
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
-
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
-
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Trading Information
- Previous Close Price
- $5.34
- Day Range
- $5.19–5.59
- 52-Week Range
- $0.72–6.10
- Bid/Ask
- $5.21 / $5.45
- Market Cap
- $219.94 Mil
- Volume/Avg
- 276,658 / 571,215
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.rezolutebio.com
Comparables
Valuation
|
Metric
|
RZLT
|
EQRX
|
NVCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.02 | 0.97 | 8.30 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RZLT
EQRX
NVCT
Financial Strength
|
Metric
|
RZLT
|
EQRX
|
NVCT
|
|---|---|---|---|
Quick Ratio | 11.56 | 18.43 | 2.74 |
Current Ratio | 12.00 | 18.78 | 2.75 |
Interest Coverage | — | — | — |
Quick Ratio
RZLT
EQRX
NVCT
Profitability
|
Metric
|
RZLT
|
EQRX
|
NVCT
|
|---|---|---|---|
Return on Assets (Normalized) | −43.56% | −15.72% | −85.22% |
Return on Equity (Normalized) | −47.94% | −16.71% | −115.93% |
Return on Invested Capital (Normalized) | −51.91% | −21.31% | −120.14% |
Return on Assets
RZLT
EQRX
NVCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Trtzdpky | Bmdccs | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rdzlkdvgq | Tjfmmd | $111.3 Bil | |||
| Moderna Inc
MRNA
| Jxscgntb | Qtpz | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Wwkpcsn | Wlxnn | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Csrnmch | Fzkj | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dmxtcfhj | Pdhyfb | $19.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nczttlpb | Gfknjxc | $15.3 Bil | |||
| Incyte Corp
INCY
| Qcvlwfpl | Gnytf | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sytxnvgzb | Ytzwk | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Hjgrqpv | Tncpb | $12.2 Bil |